As a result of these studies, direct inhibition of ABC transporter activity has become an appealing undertaking for researchers in the development of improved cancer chemotherapeutics; however, several clinical trials using ABC inhibitors have proven unsuccessful [46]. Here, ABCB6 is linked to cancer.